Kyowa Hakko U.S.A. Focuses on Cognizin™ Research at SupplySide East

May 14, 2004

Researcher says Cognizin™ will increase in dietary supplement use

New York, N.Y. – Dr. Alexander Schauss, director of Natural and Medicinal Products Research, Life Sciences Division, American Institute for Biosocial and Medical Research Inc. in Puallyup, WA, and leading scientific expert on the health benefits of citicoline, said that it would not be surprising to see a significant rise in the use of Cognizin™, a trademarked source of citicoline in the US. Dr. Schauss made his remarks on Friday, May 7, at the SupplySide East VendorWorks seminar in Baltimore, MD.

Dr. Schuass explained that citicoline, an endogenous molecule that is an obligatory intermediary for the synthesis of phosphatidylcholine and other major phospholipids in the plasma membrane component, has been shown to have tropic action at the membrane level and has been used to improve cognitive function in several brain syndromes.

“As a dietary supplement, Cognizin™ could be used for the prevention and mitigation of neurodegenerative diseases as well as eye health concerns such as amblyopia, glaucoma and presbyopia,” Dr. Schauss said.

Cognizin™, a novel and powerful anti-aging ingredient, which recently received the Nutracon NutrAward as the best new ingredient for 2003, has been used internationally for the beneficial action toward neurodegenerative disorders associated with stroke, cerebrovascular pathology, brain aging and head trauma. Kyowa Hakko has developed new commercial production techniques of Cognizin™ using fermentation technology. Scientific studies have indicated effectiveness in treating Alzheimer’s and Parkinson’s disease and improved stroke recuperation, as well as ocular health.


« Back